Clinical Trial Detail

NCT ID NCT03991832
Title Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University Health Network, Toronto
Indications

oligodendroglioma

Advanced Solid Tumor

biliary tract cancer

adult astrocytic tumour

Therapies

Durvalumab + Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST